Utah State University

DigitalCommons@USU
Undergraduate Honors Capstone Projects

Honors Program

5-2009

Knowledge of Coumadin Use in Atrial Fibrillation Potients
Krista Skye Viau
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/honors
Part of the Agricultural and Resource Economics Commons

Recommended Citation
Viau, Krista Skye, "Knowledge of Coumadin Use in Atrial Fibrillation Potients" (2009). Undergraduate
Honors Capstone Projects. 19.
https://digitalcommons.usu.edu/honors/19

This Thesis is brought to you for free and open access by
the Honors Program at DigitalCommons@USU. It has
been accepted for inclusion in Undergraduate Honors
Capstone Projects by an authorized administrator of
DigitalCommons@USU. For more information, please
contact digitalcommons@usu.edu.

KNOWLEDGE OF COUMADIN USE IN ATRIAL
FIBRILLATION PATIENTS

by
Krista S. Viau

Thesis submitted in partial fulfillment
of the requirements for the degree
of
DEPARTMENTAL HONORS
in
Dietetics
in the Department of Nutrition and Food Sciences

Approved:

Thesis/Project Advisor
Megan Bunch, RD, MS

Departmental Honors Advisor
Janet Anderson, RD, MS

Director of Honors Program
Dr. Christie Fox

UTAH STATE UNIVERSITY
Logan, UT
Spring Semester 2009

Title of Contents
Abstract

2

Introduction

3

Research Objective

4

Review of Literature

5

Methods

11

Results

14

Discussion

15

Conclusion

17

References

18

Author Biography

20

Appendix 1

21

2

Abstract
Background: Atrial fibrillation (AF) is the most common observed arrhythmia in clinical
practice. Over the next decades, the number of people affected by AF is estimated to be
anywhere from 5.6 to over 12 million. In patients with AF, thromboembolism is a central
concern, as it can lead to stroke with significant morbidity and mortality. Coumadin
anticoagulation has been shown to significantly reduce stroke risk, particularly in patients with
other risks, such as hypertension, diabetes, prior stroke, or heart failure. Although Coumadin is
effective in reducing stroke, its chronic use requires frequent international normalized ratio
(INR)/protime monitoring. This is necessary because nutritional status, compliance, and drug
interactions can lead to under- or over-coagulation. There can be numerous interactions with
food and medications in patients using Coumadin. In addition, Coumadin carries with it the
major concern of intracranial bleeding. Consequently, identifying knowledge deficits related to
Coumadin use is critical to improving patient outcomes.
Methods: This study took place at Intermountain Medical Center, Murray, Utah, in collaboration
with Utah State University, Logan, Utah. Patients with known AF, who were receiving treatment
from the Utah Heart Clinic (n=75), were asked to complete a one-time questionnaire. The data
thus obtained was analyzed to identify any knowledge deficits related to Coumadin use.
Results: It was found that 90.7 percent of the sample had at least one stroke risk factor.
Descriptive data indicated 21.3 percent of all participants reported consuming grapefruit and/or
grapefruit juice and were unaware of the interaction with Coumadin.
Conclusions: This is of great clinical significance as lack of knowledge increased the risk for
thromboembolism and intracranial bleeding. The results may be skewed due to the common
knowledge of grapefruit-drug interactions. We conclude that better strategies need to be devised
to effectively educate AF patients on Coumadin to improve treatment outcomes in the future.
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Research Objective
Patient outcomes can be improved through intervention and education pertaining to
nutrition, compliance, and understanding of drug interactions. Variability in dietary
consumption of vitamin K destabilizes anticoagulation control of Coumadin. Consumption of
grapefruit alters the metabolism of the drug and can lead to intracranial bleeding. Many
prescription drugs, over-the-counter medications, and herbal products/supplements interact with
the metabolism of Coumadin and can lead to over- or under-anticoagulation. Noncompliance
with Coumadin has been estimated at 21 percent in the elderly, who often perceived that they
were more compliant than they actually were. Patient education communicating these ideas is
widely available and frequently used for patients with cardiovascular disease but is neither
widely available nor frequently used for patients taking Coumadin. The objective ofthis study is
to assess the understanding of the AF population related to their role in reducing the risks

associated with Coumadin and the effects of proper understanding on stroke risk.
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Introduction
Atrial fibrillation (AF) is the most commonly observed arrhythmia in clinical practice.
Over the next decades, the number of people affected by AF is estimated to be anywhere from
5.6 to over 12 million (1,2). While age is a key risk factor for AF, other population
demographics will also likely contribute to the increased AF prevalence. Both the Framingham
study and a cohort from Olmsted County, Minnesota have shown age-adjusted increases in the
prevalence and incidence of atrial fibrillation from the 1960's to 1989 (3-4). The epidemiologic
changes of AF are a global phenomena with incidence and prevalence data from the Netherlands
similar to the US. AF admissions are also on the rise in China (5-6).
In patients with AF, thromboembolism is a central concern as it can lead to stroke with
high rates of morbidity and mortality. Coumadin anticoagulation has been shown to significantly
reduce stroke risk, particularly in those with other risk factors of stroke such as hypertension,
diabetes, prior stroke, or heart failure (7-11). Although Coumadin is effective in reducing stroke,
its chronic use requires frequent INR/protime monitoring. Nutritional status, hepatic function,
intestinal absorption, compliance, and genetic polymorphisms are factors that can lead to under
or overanticoagulation with long-term use of Coumadin. There are also numerous dietary and
medication interactions and the major concern of intracranial bleeding, all of which could lead to
stroke (12).
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Review of Literature
It is generally accepted that certain foods may interact with the pharmacokinetics of
certain medications (13). In 1991, researchers inadvertently discovered the drug-grapefruit juice
interaction that enhances the area under the concentration time curve (AUC) and the maximum
plasma concentration (Cmax) of orally administered drugs (13). Drugs with lower oral
bioavailability are affected to a greater degree. This interaction has been reported with 40
pharmaceutical products, including the vitamin K antagonist, Coumadin (13).
Subsequent investigations of this interaction indicated that grapefruit juice acts by
inhibiting cytochrome P450 3A4 (CYP3A4) expression (14). Cytochrome 450 (CYP450)
enzymes are in a class of over 50 enzymes. Six of those are responsible for metabolizing 90
percent of drugs, with the two most significant enzymes being CYP3A4 and CYP2D6 (15).
Drug metabolism may be the result of one or several CYP450 enzymes. For example,
Coumadin is metabolized by CYPIA2, CYP2D6, and CYP3A4 (15). Drugs that interact with
CYP450 enzymes are known as either inhibitors or inducers. Inhibitors block the activity of one
or more CYP450 enzymes, amplifying the effect of the drug (15). A drug can both inhibit an
enzyme and be metabolized by the same enzyme. Conversely, inducers enhance the synthesis of
CYP450 enzymes, thus reducing the drug's effect. Adverse effects are more common if the drug
has a narrow safety range and if it is metabolized by only one enzyme (15).
Grapefruit juice inhibits CYP3A4 synthesis and accelerates CYP3A4 degradation, which
indicates the process is mechanism-based opposed to competitive (13). Mechanism-based
inhibition involves an inhibitor being metabolically activated by an enzyme and then irreversibly
inactivating that same enzyme. This means that the return of enzyme activity wiIl require de
novo enzyme synthesis and prolong the effect of the inhibitor (13). For this reason, the effects of
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grapefruit juice typically last 24 hours (14). Drug-grapefruit juice interactions, therefore, cannot
be fully avoided by taking them at a different time (16).
Drug-grapefruit juice interactions are unique in that while apical enterocytes and
hepatocytes both contain CYP3A4, ingestion of normal amounts of grapefruit juice only appears
to alter intestinal CYP3A4 expression (14). Studies demonstrated a 62 percent reduction in
intestinal CYP3A4 protein content after consuming grapefruit juice over 5 days (14). However,
repeated dosing of large amounts of grapefruit juice over several days can also inhibit hepatic
CYP3A4 synthesis (16). The content of intestinal and hepatic CYP3A4 can vary tenfold among
individuals and appears to be regulated independently of the other. Therefore, the magnitude of
the interaction is highly variable (14).
Identification of the active ingredients in grapefruit juice is important, as it would enable
researchers to evaluate its effect on CYP3A4 with other foods. In addition, the active ingredients
may be used in commercial products to produce higher drug bioavailability (14). Several
components of grapefruit juice have been proposed as the cause of this interaction, including
flavonoids and furanocoumarins.
The most prevalent flavonoid in grapefruit juice is naringin (14). Naringin is in high
concentration in grapefruit juice and absent from orange juice, which does not interact with
Coumadin. While naringin has potential to inhibit CYP3A4 synthesis, it is less potent than its
aglycone, naringenin (14). Naringenin is typically not present in grapefruit juice, but studies
demonstrated renal excretion of naringenin conjugates after administration of grapefruit juice,
suggesting in vivo naringenin formation. However, ingestion of commercial pure naringin in the
same amounts as grapefruit juice produced little to no effect (14).
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More recent studies concluded that furanocoumarins are the major CYP3A4 inhibitors in
grapefruit juice. Bergamottin and 6' ,7' -dihydroxybergamottin (DHB) are the two most abundant
furanocoumarins in grapefruit juice (17). In order to accurately evaluate their impact on
CYP3A4 inhibition, a furanocoumarins-free (FC-free) formula was created. The recorded results
reported the ADC of grapefruit juice to be 30 to 370 percent higher than that of the FC-free
grapefruit juice (17). The FC-free formula behaved in a similar manner to orange juice. It
produced some effects, but to a much lesser degree (17). While furanocoumarins appear to be
the active ingredient in grapefruit juice, no individual furanocoumarin is able to completely
reproduce the inhibitory effect of whole juice. It is not possible to determine which
furanocoumarin contributes the most to the grapefruit juice-drug interaction (17).
There have been recent attempts to remove FCs from grapefruit juice, which include
chemical, physical, and microbiological methods. One of these methods involves the use of
autoclaved fungus to absorb and remove FCs, specifically M. esculenta (18). M. esculenta
efficiently absorbed all non-polar FCs in grapefruit juice. However, polar FCs were not
absorbed, which caused 40% of the CYP3A4 inhibition to remain (18). The binding of FCs to
the fungi is believed to be due to passive interaction. This interaction was successful in
reducing the potency of the inhibitory effect of grapefruit juice on CYP3A4 (18).
The vitamin K antagonist Coumadin has multiple food-drug and drug-drug interactions,
including grapefruit juice. Coumadin is the most extensively used oral anticoagulant worldwide.
It is indicated to prevent thromboembolism, myocardial infarction, and stroke in patients with
atrial fibrillation (AF) and prosthetic heart valves (19). AF increases the risk of stroke five-fold.
Coumadin reduces the risk of AF-related stroke by 64 to 70 percent (20).
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Coumadin acts by inhibiting the vitamin K-dependent coagulation factors II, VII, IX, and
X. The drug is promptly absorbed and its concentration peaks around 4 hours (19). Coumadin is
eliminated through metabolism by hepatic CYP2C9. There are several variations in the gene that
encodes CYP2C9 among different ethnic groups. These variants are associated with an increase
in negative clinical outcomes, including over- and under-anticoagulation, both of which can lead
to stroke (19). Inadequate amounts of Coumadin can increase the risk for a thromboembolism
leading to an ischemic stroke. An abundance of Coumadin can increase the risk of intracranial
bleeding, which could cause a hemorrhagic stroke (19).
The dose-response to Coumadin has a large range due to intrinsic genetic factors,
comorbid diseases, other medications, and dietary factors, all of which can alter drug
metabolism. While grapefruit juice can significantly amplify the effects of Coumadin, it does
not appear to alter the anticoagulant response (19). Due to the wide dose-response of Coumadin
and the wide dose-response of grapefruit juice, medical professionals cannot safely recommend a
specific amount of grapefruit juice that one could ingest while taking Coumadin.
The current patient education methods utilized in health care facilities may not be
adequate to convey the importance of adherence to the prescription and the seriousness and
understanding of food-drug interactions, especially concerning grapefruit juice. Adverse effects
of Coumadin are common with non-adherence. Poor adherence is estimated to cause 5 percent
of all hospital admissions, which accrue 8 billion dollars in cost every year (20). Anticoagulants
are believed to be the leading cause of preventable adverse drug-related events among the
elderly.
The INR Adherence and Genetics (IN-RANGE) study demonstrated that over 40 percent
of participants were less than 80 percent adherent with their Coumadin prescription (20).
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Overall non-adherence was significantly associated with underanticoagulation and altered INR
levels. No differences were found when examining compliance with initiation versus
maintenance of Coumadin. These findings are significant as even moderate fluctuations in INR
are associated with increased risk of thromboembolism, additional visits, increased need for dose
changes, and a higher potential for dosing errors (20).
The latest results from the IN-RANGE study lend support to the hypothesis of poor
compliance among those taking Coumadin. Non-adherence was reported in 21 percent of the
days observed, with individual numbers ranging from 0.9 to 79 percent (21). Increased non
adherence was significantly associated with those with education beyond a high school diploma,
those with active employment, and those with lower cognitive functioning.
Poor adherence in educated populations may be due to more independent decision
making or decreased trust in physicians (21). The negative association with employment and
medication adherence is consistent with other studies and other disease settings. While the
underlying relationship is not definite, it is hypothesized that employment may represent several
factors, which take priority over consistent pill taking (21). Lower cognitive function was
associated with non-adherence, but there was no association with depressive symptoms. Patient
adherence to Coumadin appears to be related to factors involving time, memory, and mental
health functioning (21).
Health literacy may also playa role in patient compliance and understanding. Previous
studies demonstrated decreased patient knowledge and lack of Coumadin education are
associated with reduced anticoagulant control and increased risk of hemorrhagic events (22).
Health education brochures are typically written at a ninth-grade level or higher. A recent study
demonstrated that out of 179 interviewed patients, 33.5 percent reported having no more than an
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eighth-grade level education (22). Limited health literacy was prevalent in 60.9 percent of the
multi-cultural population and was more likely to occur in those that were older, female, non
white, and have less than a high school education.
Limited health literacy increased the amount of incorrect answers concerning Coumadin
related knowledge (22). The patients taking Coumadin for atrial fibrillation were more likely to
report that their physician had not explained that they had atrial fibrillation (60 percent vs.
9.7percent) and were less likely to understand that it increased their risk of stroke (42 percent vs.
70 percent). Despite these differences, limited health literacy was not significantly associated
with poor INR control (22).
Coumadin is a beneficial but potentially hazardous medication. Appropriate education
has a profound impact on patient knowledge of Coumadin use, INR control, and prevalence of
drug-related complications.
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Methods
This study was conducted at Intennountain Medical Center (Murray, Utah) in
collaboration with Utah State University (Logan, Utah). Patients with known AF who were
receiving treatment from the Utah Heart Clinic (n=75) and were currently taking Coumadin were
asked to complete a one-time questionnaire of 52 questions. The questionnaire was completed
under the supervision of a registered dietitian or student dietitian. Data collected was analyzed to
assess the descriptive characteristics of the data and to identifY any knowledge deficits related to
Coumadin use and was stratified based on stroke risk versus non-stroke risk. This study was
approved by the Institutional Review Board at Utah State University (protocol #2187).
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Results
The mean age of the patient population was 69.2 (n=75). The data was stratified by
gender to assess differences between male and female. The patients were categorized according
to stroke risk, based on the CHADS2 Score. The CHADS2 score is used to estimate risk of stroke
in AF patients.
Sixty-eight of the patients had at least one risk factor for stroke (see Table 1). The seven
remaining patients with no stroke risk factors were taking Coumadin because they had recently
undergone a cardiac ablation.
Hypertension was the most common stroke risk factor (58.7 percent of the population).
Age> 75 years was the second most common, followed by heart failure.

Table 1. Stroke Risk Characteristics

Item

M+F
n(%)

M
n(%)

F
n(%)

n
Age

75
69.2

47
66.7

28
72.3

44(58.7)
25(33.3)
26(34.7)
12(16.0)
19(25.3)
6(8.0)

28(59.6)
14(29.8)
12(25.5)
7(14.9)
11(23.4)
3(6.6)

16(57.1)
11(39.3)
14(50.0)
5(17.9)
8(28.6)
3(10.7)

Stroke Risk
1. Hypertension
2. Heart failure
3. Age >75
4. Diabetes
5. TIA
7. TIA on Coumadin

Table 2 represents the patient population (n=16) who reported having consumed
grapefruit or grapefruit juice and were not aware that grapefruit interacts with Coumadin.
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Possible responses to the grapefruit or grapefruit juice consumption question ranged from "every
day" to "less than once a month." Table 2 reveals that 21.3 percent of those that consumed
grapefruit or grapefruit juice were unaware of this interaction.

Table 2. Those Who Were Not Aware Of Grapefruit Interaction With Coumadin

Item

M+F
n(%)

M
n(%)

F
n(%)

Grapefruit

16(21.3)

10(21.3)

6(21.4)

Table 3 presents the data from the grapefruit or grapefruit consumption question only
with respect to members of the population having stroke risk (n=68). Surprisingly, there was no
difference in the proportion (21.3 percent) that were not aware of the grapefruit interaction with
Coumadin.

Table 3. Those At Stroke Risk Who Were Not Aware Of Grapefruit Interaction With
Coumadin

Item

M+F
n(%)

M
n(%)

F
n(%)

Grapefruit

16(21.3)

10(21.3)

6(21.4)
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Discussion
Seventy-five patients participated in this study. Of these, 68 had at least one stroke risk
factor, which included hypertension, heart failure, age over 75 years, diabetes, and prior stroke.
The study demonstrated that 21.3 percent of those who consumed grapefruit or grapefruit juice
were not aware of its interaction with Coumadin. While this study was the first to assess patient
knowledge of specific drug-nutrient and drug-drug interactions, our results are similar with other
research assessing overall patient understanding of Coumadin (23).
A recent study demonstrated that 83 percent of patients were aware that too little
Coumadin could lead to an ischemic stroke, but only 21 percent were aware that too much could
lead to a hemorrhagic stroke (23). Thirteen percent of patients did not know that Coumadin
could cause bruising or internal bleeding. Patient beliefs also included 12 percent claiming they
were able to determine if the Coumadin was at the right level by how they felt and 13 percent
stating that missing a lab appointment was not that important (23).
Appropriate education tools are essential to overcome these barriers. There has been
debate about the effectiveness of presenting statistics in educational materials compared with
narratives (23). A growing amount of literature suggests that even well educated patients
struggle comprehending quantitative information. Narratives may be more engaging,
memorable, and realistic than statistics, but may induce inaccurate beliefs or lead to non-optimal
decision-making (23).
Patients viewing a video education tool with evidence presented in a narrative format
showed greater knowledge gains than those that received statistical evidence (p=O.OO6). There
were no significant differences in the narrative version compared to the video with narrative plus
statistical evidence (23). Narrative evidence may be more effective in Coumadin education. The
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videos used in this study did have a positive impact; however, they did not correct knowledge
gaps, reduce incorrect beliefs, or improve non-adherence. Patients may benefit from periodic
Coumadin education. Clinicians should not assume that those who have been taking Coumadin
for months or years have adequate knowledge of its drug-nutrient and drug-drug
interactions (23).
The results of this study may have been skewed by common knowledge that grapefruit
interacts with most medications, especially many cardiovascular and hypertensive agents. With
that in mind while completing the questionnaire, the participants may have merely guessed,
rather than answering based on their specific knowledge, that Coumadin interacts with
grapefruit.
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Conclusion
This is the first study to assess and compare the association of various risk factors with
Coumadin knowledge. Stroke risk patients (n=68) had limited knowledge related to Coumadin
use. As most patients had at least one stroke risk factor, comparison of stroke risk patients and
their non-stroke counterparts was not possible. AF patients did not ask professionals about
Coumadin interactions. Specifically, 21.3 percent of those consuming grapefruit or grapefruit
juice did not ask a professional if the product interacts with Coumadin. Only 63.9 percent of
participants were knowledgeable about at least one dietary influence on Coumadin metabolism.
Lack of patient knowledge may increase the risk for thromboembolism and intracranial
bleeding in patients taking Coumadin. Dietary factors, drug compliance, and interactions with
Coumadin can be positively influenced through intervention and education. Better strategies
need to be devised to effectively educate AF patients on Coumadin to improve treatment
outcomes in the future. Further data analysis will take place to identify specific correlations in
order to improve patient education in the future.
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Survey Instrument
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Age

_

Please circle:

Gender
Male
Female

Education Level
Less than the 8th Grade
8-12th Grade
High School Graduate
College Graduate
Advanced Degree

Stroke Risk Factors
1. High blood pressure: YeslNo
2. Heart failure: YeslNo
3. Age greater than 75 years: YeslNo
4. Diabetes: YeslNo
5. Prior stroke or mini-stroke (TIA): YeslNo
7. Prior stroke or mini-stroke when on Coumadin: YeslNo
If you had a stroke on Coumadin, was your blood level:
a. Too low
b. Normal
c. Too high
d. Not sure

1

Other Cardiac Problems
1. Have you had a prior heart attack: YeslNo
2. Have you had a stent or bypass surgery: Yes/No
3. Do you have any problems with your heart valves: Yes/No
If yes, was the problem:
a. Narrow
b. Leaky
c. Not sure
4. Have you had surgery for your heart valves: YeslNo

Please answer the following questions:

1. Have you ever experienced bleeding in your urine or stools? YeslNo

2. Have you ever received a blood transfusion because of bleeding? Yes/No

3. Have you fallen in the past year? Yes/No

4. If you have fallen in the past year, how many times? _ _

5. How long have you been on Coumadin?
a. Less than 1 year
b. 1 year - 5 years
c. 5 years - 10 years
d. Greater than 10 years
e. Not sure

2

6. Do you take your Coumadin as prescribed by your doctor? YeslNo

7. Do you ever skip your Coumadin dose? YeslNo

8. Do you ever double up your Coumadin dose? YeslNo

9. Do you ever not refill your Coumadin because of cost? YeslNo

10. What is the most common reason why you may not take your Coumadin dose?
a. Cost
b. Forgetting
c. Mixing up medications
d. Lack of desire
e. Illness
f. None of the above

11. Have you gained weight after starting Coumadin? YeslNo

12. If yes, approximately how much weight have you gained? _ _

13. If yes, why do you think you gained the weight? (Circle all that apply)
a. Changed diet and avoided vegetables
b. Exercised less
c. Ate more at each meal
d. Craved new foods that were less healthy

3

14. Have you lost weight after starting Coumadin? Yes/No

15. If yes, approximately how much weight have you lost? _ _

16. If yes, why do you think you lost the weight? (Circle all that apply)
a. Changed diet and avoided many foods
b. Illness
c. Ate less at each meal
d. Stopped drinking alcohol

17. What is considered a normal INR (blood Coumadin level)?
a. Less than 1

b.2-3
c.4-5
d. Greater than 5
e. Not sure

18. Do you know what your current INR (blood Coumadin level) is? Yes/No

19. Approximately how often do you get your INR (blood Coumadin level) checked?
a. Once a week
b. Twice a month
c. Once a month
d. Twice a year
e. Once a year
d. Never
f. Not sure
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20. Do you ever not get your INR (blood Coumadin level) checked because of cost?
YeslNo

21. Are you aware that your other medications can interact with Coumadin? YeslNo

22. Do you ask your pharmacist before starting a new medication if it interacts with
Coumadin? Yes/No

23. Do you ever take over-the-counter pain medications? YeslN 0

24. If yes, which ones? (Circle all that apply)
Excedrin®

Tylenol® (Acetaminophen)

Aleve® (Naproxen)

Advil® (Ibuprofen)

Motrin® (Ibuprofen)

Aspirin

25. Do you ask your doctor before using over-the-counter pain medications? YeslNo

26. Do you ever take over-the-counter stomach remedies? Yes/No

27. If yes, which ones? (Circle all that apply)
Tagamet HB® (Cimetidine) Pepto Bismol® (Bismuth Subsalicyclate)
Laxatives

Stool Softeners

Alka-Seltzer®

28. Do you ask your doctor before using over-the-counter stomach remedies? Yes/No

29. Do you take vitamin supplements? Yes/No
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30. If yes, which ones (Circle all that apply)
Multivitamin (Dose:

)

Vitamin A (Dose:

)

Vitamin E (Dose:

)

Vitamin D (Dose:

)

Vitamin C (Dose:

)

31. Are you aware that vitamin supplements can interact with Coumadin? Yes/No

32. Do you ask your doctor before using a vitamin supplement if it interacts with
Coumadin? Yes/No

33. Do you think getting enough Vitamin K is important?
a. Yes
b.No
c. Not sure

34. What do you think Vitamin K does for us? (Circle all that apply)
a. Improves eye sight
b. Strengthens bones
c. Improves the texture and softness of skin
d. Helps to form clots
e. It is an anti-oxidant to help the body

35. Do you take any herbal or natural medications or supplements? Yes/]\To
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36. If yes, which ones? (Circle all that apply)
Garlic

Ginger

Glucosarnine

Ginko Biloba

CoEnzyme Q10

Green Tea

St. John's Wort

Flaxseed

Melatonin

Papaya Extract

Ginseng

Soy Protein Products

Fish oil supplements that contain EPA or DHA

37. Are you aware that natural medications or supplements can interact with Coumadin?
YeslNo

38. Do you ask your doctor before using a natural medication or supplement if it interacts
with Coumadin? YeslNo

39. Do you know how to interpret a supplement facts label on natural medications or
supplements? YeslNo

40. How often do you drink alcoholic beverages?
a. Every day
b. 4-6 days a week
c. 2-3 days a week
d. Once a week
e. 2-3 times a month
d. Once a month
e. Less than once a month
f. Never
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41. How often do use tobacco products?
a. Every day
b. 4-6 days a week
c. 2-3 days a week
d. Once a week
e. 2-3 times a month
d. Once a month
e. Less than once a month

f. Never

42. Can changing your diet change your Coumadin dose?

a. Yes
b.No
c. Not sure

43. How often do drink grapefruit juice or eat grapefruit?
a. Every day
b. 4-6 days a week
c. 2-3 days a week
d. Once a week
e. 2-3 times a month
d. Once a month
e. Less than once a month
f. Never
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44. Are you aware that grapefruit and grapefruit juice interact with Coumadin?
a. Yes
b.No
c. Not sure

45. Are you aware that you get Vitamin K from the foods you eat?
a. Yes
b.No
c. Not sure

46. How much Vitamin K do the following foods contain? Please circle the amount:
Cooked broccoli
(l cup)

0-9 meg

10-29 meg

30-89 meg

99-1200 meg

Vegetable Oil (l
Tbsp)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Canned tuna in
oil (3 oz)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Iceberg lettuce (l
cup)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Cooked spinach
(l cup)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Coleslaw (3/4
cup)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Red grapes (l
cup)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Green leaf
lettuce (1 cup)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Walnuts (14
halves)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Grapefruit juice
(l cup)

0-9 meg

10-24 meg

25-99 meg

100-499 meg
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Red wine (3.5 f1
oz)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Olive Oil (1
tbsp)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Cooked
asparagus (4
spears)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Raw celery (l
stalk)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Vanilla ice
cream (1/2 cup)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Avocado (3 oz)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

75% lean ground
beef(30z)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Roasted chicken
(l drumstick)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Raw pineapple
(l cup)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Cooked salmon
(1/2 fillet)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Swiss cheese (1
oz)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

2% milk (1 cup)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Hard-boiled egg
(llarge)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

Chunky peanut
butter (l Tbsp)

0-9 meg

10-24 meg

25-99 meg

100-499 meg

47. Do you know how to interpret a nutrition facts label on food products? YeslNo
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48. How many meals do you eat each day?
a. One
b. Two
c. Three
d. Four
e. Five
f. Less than one
g. More than 5

49. How many meals do you eat each day with Vitamin K?
a.One
b. Two
c. Three
d. Four
e. Five
f. Less than one
g. More than 5
h. Not sure

50. Is it important to watch how much Vitamin K you get each day when you are on
Coumadin?
a. Yes
b.No
c. Not sure

51. Do you believe that taking Coumadin negatively influences your quality of life?
Yes/No
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52. If yes, why do you think Coumadin negatively influences your quality of life? (Circle
all that apply)
a. Frequent blood draws
b. Don't get to eat your favorite foods
c. Diet is too restrictive
d. No longer drink alcohol or only occasionally
e. Worry about bleeding
f. Feel unwell or experience side effects on the medication
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